Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Change in Receivables came in at $46000.0 in Q4 2025, down 45.88% year-on-year from $85000.0 in Q4 2024, and up 136.22% on a QoQ basis from -$127000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Change in Receivables data on file, last reported at $46000.0 in Q4 2025.
- On a quarterly basis, Change in Receivables fell 45.88% year-over-year to $46000.0 in Q4 2025; TTM through Dec 2025 was -$200000.0, a 208.11% decrease from a year earlier, with the FY2025 full-year figure at -$200000.0, down 208.11% from the prior year.
- Change in Receivables for Q4 2025 stood at $46000.0, up from -$127000.0 in the prior quarter.
- Over the last five years, Change in Receivables for INBX reached as high as $447000.0 in Q4 2023 and fell as low as -$183000.0 in Q1 2025.
- Historically, Change in Receivables has averaged $54500.0 across 3 years, with a median of $55000.0 in 2025.
- Across the five-year window, Change in Receivables sank 80.98% in 2024 and tumbled 36.0% in 2025, its largest moves.
- Year by year, Change in Receivables stood at $447000.0 in 2023, then sank by 80.98% to $85000.0 in 2024, then slumped by 45.88% to $46000.0 in 2025.
- Per Business Quant data, the three most recent Change in Receivables figures were $46000.0 in Q4 2025, -$127000.0 in Q3 2025, and $64000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Dec 31, 2023 | 447,000.00 |
| Dec 31, 2023 | 447,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |